Abstract
Objectives: To determine whether doxorubicin-piroxicam combination is safe and has activity against transitional cell carcinoma in dogs. Methods: Data was collected retrospectively from 34 dogs from two institutions over a 6-year period. Signalment, clinical presentation, treatment specifics, adverse events, response, progression-free survival and overall survival time were evaluated. Results: Dogs received doxorubicin every 3 weeks and daily piroxicam; 17 dogs (50%) had surgery. Clinical presentations were those typically reported for transitional cell carcinoma. Mean number of doses administered was 3·5. Of the 23 dogs with measurable disease, 14 (60·5%) had stable disease, 7 (30·5%) had progressive disease and 2 (9%) a partial response. Adverse events were generally manageable, and gastrointestinal in origin; one dog died of treatment-related complications. Overall median progression-free survival and overall survival were 103 and 168 days, respectively. Cytoreductive surgery did not result in prolongation of progression-free survival, but significantly prolonged overall survival. All dogs but one died as a result of disease progression. Clinical Significance: Doxorubicin-piroxicam combination therapy is well-tolerated in dogs with transitional cell carcinoma although progression-free survival, overall survival and biological response rates appear modest. Combination with surgery appears to offer a survival advantage; however, this may reflect tumour location and volume. Prospective studies are necessary to compare activity of combination doxorubicin-piroxicam to currently applied therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 67-74 |
| Number of pages | 8 |
| Journal | Journal of Small Animal Practice |
| Volume | 54 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2013 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Small Animals
Cite this
Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs. / Robat, C.; Burton, Jenna H; Thamm, D.; Vail, D.
In: Journal of Small Animal Practice, Vol. 54, No. 2, 02.2013, p. 67-74.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs
AU - Robat, C.
AU - Burton, Jenna H
AU - Thamm, D.
AU - Vail, D.
PY - 2013/2
Y1 - 2013/2
N2 - Objectives: To determine whether doxorubicin-piroxicam combination is safe and has activity against transitional cell carcinoma in dogs. Methods: Data was collected retrospectively from 34 dogs from two institutions over a 6-year period. Signalment, clinical presentation, treatment specifics, adverse events, response, progression-free survival and overall survival time were evaluated. Results: Dogs received doxorubicin every 3 weeks and daily piroxicam; 17 dogs (50%) had surgery. Clinical presentations were those typically reported for transitional cell carcinoma. Mean number of doses administered was 3·5. Of the 23 dogs with measurable disease, 14 (60·5%) had stable disease, 7 (30·5%) had progressive disease and 2 (9%) a partial response. Adverse events were generally manageable, and gastrointestinal in origin; one dog died of treatment-related complications. Overall median progression-free survival and overall survival were 103 and 168 days, respectively. Cytoreductive surgery did not result in prolongation of progression-free survival, but significantly prolonged overall survival. All dogs but one died as a result of disease progression. Clinical Significance: Doxorubicin-piroxicam combination therapy is well-tolerated in dogs with transitional cell carcinoma although progression-free survival, overall survival and biological response rates appear modest. Combination with surgery appears to offer a survival advantage; however, this may reflect tumour location and volume. Prospective studies are necessary to compare activity of combination doxorubicin-piroxicam to currently applied therapies.
AB - Objectives: To determine whether doxorubicin-piroxicam combination is safe and has activity against transitional cell carcinoma in dogs. Methods: Data was collected retrospectively from 34 dogs from two institutions over a 6-year period. Signalment, clinical presentation, treatment specifics, adverse events, response, progression-free survival and overall survival time were evaluated. Results: Dogs received doxorubicin every 3 weeks and daily piroxicam; 17 dogs (50%) had surgery. Clinical presentations were those typically reported for transitional cell carcinoma. Mean number of doses administered was 3·5. Of the 23 dogs with measurable disease, 14 (60·5%) had stable disease, 7 (30·5%) had progressive disease and 2 (9%) a partial response. Adverse events were generally manageable, and gastrointestinal in origin; one dog died of treatment-related complications. Overall median progression-free survival and overall survival were 103 and 168 days, respectively. Cytoreductive surgery did not result in prolongation of progression-free survival, but significantly prolonged overall survival. All dogs but one died as a result of disease progression. Clinical Significance: Doxorubicin-piroxicam combination therapy is well-tolerated in dogs with transitional cell carcinoma although progression-free survival, overall survival and biological response rates appear modest. Combination with surgery appears to offer a survival advantage; however, this may reflect tumour location and volume. Prospective studies are necessary to compare activity of combination doxorubicin-piroxicam to currently applied therapies.
UR - http://www.scopus.com/inward/record.url?scp=84873126381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873126381&partnerID=8YFLogxK
U2 - 10.1111/jsap.12009
DO - 10.1111/jsap.12009
M3 - Article
C2 - 23286739
AN - SCOPUS:84873126381
VL - 54
SP - 67
EP - 74
JO - Journal of Small Animal Practice
JF - Journal of Small Animal Practice
SN - 0022-4510
IS - 2
ER -